Status:

RECRUITING

Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant

Lead Sponsor:

Children's Hospital Medical Center, Cincinnati

Conditions:

Fragile X Syndrome

Eligibility:

All Genders

6-26 years

Phase:

NA

Brief Summary

Individuals with Fragile X Syndrome show differences in how they understand and learn language from infancy. They frequently have lifelong delays in speech and language as well. In addition, they expe...

Detailed Description

Fragile X Syndrome (FXS) is the leading monogenic cause of intellectual disability and autism and is associated with extremely high risk for early delays in speech and language. While infancy is essen...

Eligibility Criteria

Inclusion

  • Diagnoses of Fragile X Syndrome, Typical Development, or History of Premature Birth
  • able to sit independently
  • English is spoken at home

Exclusion

  • For all participants: no seizures in the past 6 months
  • For typical development group and Fragile X group: not born prior to 32 weeks gestation

Key Trial Info

Start Date :

October 31 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 31 2026

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06560242

Start Date

October 31 2022

End Date

October 31 2026

Last Update

August 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cincinnati Children's Hospital

Cincinnati, Ohio, United States, 45229